--- title: "Surrogate Endpoint, Definition | MedTech Terms" description: "Biomarker or intermediate outcome used as a substitute for a clinical endpoint in regulatory decisions. Plain-English Clinical & Trials definition for MedTech t" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/surrogate-endpoint#term", "name": "Surrogate Endpoint", "description": "Surrogate endpoints (e.g., HbA1c for glycemic control, blood pressure for cardiovascular risk) shorten trial duration but require evidence that change in the surrogate predicts clinically meaningful benefit.", "url": "https://medtechterms.com/terms/surrogate-endpoint", "termCode": "surrogate-endpoint", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/surrogate-endpoint#article", "headline": "Surrogate Endpoint", "description": "Biomarker or intermediate outcome used as a substitute for a clinical endpoint in regulatory decisions.", "url": "https://medtechterms.com/terms/surrogate-endpoint", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/surrogate-endpoint" }, "about": { "@id": "https://medtechterms.com/terms/surrogate-endpoint#term" }, "articleSection": "Clinical & Trials", "inLanguage": "en", "keywords": "Surrogate Endpoint, Clinical & Trials, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "FDA Surrogate Endpoints", "url": "https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure", "publisher": { "@type": "Organization", "name": "FDA" } }, { "@type": "CreativeWork", "name": "ISO 14155 Standard Page", "url": "https://www.iso.org/standard/71690.html", "publisher": { "@type": "Organization", "name": "ISO" } }, { "@type": "CreativeWork", "name": "FDA - Clinical Trials and Human Subject Protection", "url": "https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection", "publisher": { "@type": "Organization", "name": "FDA" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/mcid#term", "name": "Minimal Clinically Important Difference", "alternateName": "MCID", "url": "https://medtechterms.com/terms/mcid" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/composite-endpoint#term", "name": "Composite Endpoint", "url": "https://medtechterms.com/terms/composite-endpoint" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Clinical & Trials", "item": "https://medtechterms.com/terms?cat=Clinical%20%26%20Trials" }, { "@type": "ListItem", "position": 4, "name": "Surrogate Endpoint", "item": "https://medtechterms.com/terms/surrogate-endpoint" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/surrogate-endpoint#faq", "mainEntity": [ { "@type": "Question", "name": "Why are surrogate endpoints used in MedTech clinical trials?", "acceptedAnswer": { "@type": "Answer", "text": "Surrogate endpoints are used to shorten the duration and reduce the cost of clinical trials by providing an earlier indication of a treatment's effect, particularly for diseases with long-term primary outcomes." } }, { "@type": "Question", "name": "What is the primary regulatory concern with surrogate endpoints?", "acceptedAnswer": { "@type": "Answer", "text": "The primary regulatory concern is ensuring that a change in the surrogate endpoint reliably predicts a real, clinically meaningful benefit for the patient, as an unvalidated surrogate may not accurately reflect clinical improvement." } }, { "@type": "Question", "name": "How does the FDA evaluate surrogate endpoints for MedTech submissions?", "acceptedAnswer": { "@type": "Answer", "text": "The FDA evaluates surrogate endpoints based on their scientific validity, the strength of evidence demonstrating their correlation with true clinical outcomes, and their relevance to the intended use and patient population." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Clinical & Trials](/terms?cat=Clinical%20%26%20Trials) 6. / 7. Surrogate Endpoint [All terms](/terms) Clinical & Trials [Clinical Evidence](/ecosystems/clinical-evidence) # Surrogate Endpoint Biomarker or intermediate outcome used as a substitute for a clinical endpoint in regulatory decisions. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Surrogate endpoints (e.g., HbA1c for glycemic control, blood pressure for cardiovascular risk) shorten trial duration but require evidence that change in the surrogate predicts clinically meaningful benefit. What the regulation says The FDA recognizes surrogate endpoints as measures that can be used in clinical trials to predict a clinical benefit, as outlined in guidance documents such as the “Guidance for Industry, FDA Staff, and Other Stakeholders: Expedited Programs for Serious Conditions-Drugs and Biologics.” The [EU Medical Device Regulation](/terms/mdr) (EU [MDR](/terms/mdr-reporting)) does not explicitly detail surrogate endpoints; however, the principles of clinical evidence and demonstration of safety and performance (Annex I, Chapter I, Section 1 and 3) necessitate that endpoints, including surrogates, reliably demonstrate clinical benefit. Regulators emphasize that a surrogate endpoint must be validated to show it is a reasonable predictor of a clinically meaningful outcome. ## What this means in practice Increasingly important for [IVD](/terms/ivd) and digital biomarker submissions; FDA maintains a Surrogate Endpoint Table for drug approvals that informs device thinking. ## Examples - A trial for a new diabetes management app uses a reduction in HbA1c levels as a surrogate endpoint to demonstrate improved glycemic control over a shorter trial period, rather than waiting for long-term cardiovascular events. - A diagnostic test for early cancer detection utilizes a specific biomarker level as a surrogate endpoint, which has been shown to correlate with definitive pathological diagnosis. - A medical device designed to treat hypertension employs sustained reductions in blood pressure readings as a surrogate endpoint, with extensive prior evidence linking this to reduced risk of stroke and heart attack. Common pitfalls - • Over-reliance on a surrogate endpoint without sufficient clinical validation can lead to regulatory rejection. - • Selecting a surrogate endpoint that does not accurately reflect the patient population or disease progression is a common mistake. - • Failing to establish a clear and evidence-backed correlation between the surrogate endpoint and the true clinical outcome is a critical pitfall. - • Underestimating the data requirements for validating a surrogate endpoint can delay trial progress. ## Frequently asked questions Why are surrogate endpoints used in MedTech clinical trials? Surrogate endpoints are used to shorten the duration and reduce the cost of clinical trials by providing an earlier indication of a treatment's effect, particularly for diseases with long-term primary outcomes. What is the primary regulatory concern with surrogate endpoints? How does the FDA evaluate surrogate endpoints for MedTech submissions? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Clinical & Trials Composite Endpoint Single endpoint combining multiple component outcomes (e.g., MACE = death + MI + stroke). ](/terms/composite-endpoint)[ Clinical & Trials Minimal Clinically Important Difference(MCID) Smallest change in a measurement that patients perceive as clinically meaningful. ](/terms/mcid) ### Clinical Trials & Evidence · From this learning path [ Clinical & Trials Adverse Event(AE) Any untoward medical occurrence in a subject, whether or not related to the device. Adjacent lesson ](/terms/adverse-event?from=clinical-trials-and-evidence)[ Clinical & Trials Primary and Secondary Endpoints The pre-specified outcomes that determine trial success (primary), provide supporting evidence (secondary), or generate hypotheses (exploratory). Adjacent lesson ](/terms/primary-secondary-endpoint?from=clinical-trials-and-evidence)[ Clinical & Trials Adaptive Trial Design Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data. ](/terms/adaptive-trial?from=clinical-trials-and-evidence)[ Clinical & Trials Clinical Evaluation Report(CER) Documented assessment of clinical data demonstrating EU MDR conformity for a device. ](/terms/cer?from=clinical-trials-and-evidence) ### More in Clinical & Trials · Same category [ Clinical & Trials Feasibility Study Small clinical study evaluating initial safety, usability, and design parameters of an investigational device. ](/terms/feasibility-study)[ Clinical & Trials IDE Annual Progress Report Annual report sponsors must submit to FDA summarizing the progress of an approved IDE study, including enrollment, deviations, and adverse events. ](/terms/ide-annual-report) Cited by Where this term appears across MedTech Terms. Learning paths (1) - [Clinical Trials & Evidence](/paths/clinical-trials-and-evidence)Lesson 11 of 18 Ecosystems (1) - [Clinical Evidence](/ecosystems/clinical-evidence) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 FDA· 2 ISO· 1 1. [1 FDA Surrogate Endpoints Verified FDA · fda.gov ](https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure) 2. [2 ISO 14155 Standard Page Verified ISO · iso.org ](https://www.iso.org/standard/71690.html) 3. [3 FDA - Clinical Trials and Human Subject Protection Verified FDA · fda.gov ](https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Clinical evidence intersecting with device security? We support clinical-stage MedTech teams whose investigational devices touch patient data or hospital networks. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Clinical & Trials Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=surrogate-endpoint) Learn in 60 seconds Card Lesson Quiz Biomarker or intermediate outcome used as a substitute for a clinical endpoint in regulatory decisions. - · Increasingly important for IVD and digital biomarker submissions; FDA maintains a Surrogate Endpoint Table for drug approvals that informs device thinking. Remember this Watch out: Over-reliance on a surrogate endpoint without sufficient clinical validation can lead to regulatory rejection. Related terms - [Minimal Clinically Important Difference(MCID) ](/terms/mcid) - [Composite Endpoint ](/terms/composite-endpoint) You may also need Auto-suggested from Clinical & Trials and shared keywords. - [Primary and Secondary Endpoints ](/terms/primary-secondary-endpoint) - [Pivotal Trial ](/terms/pivotal-trial) - [Master Protocol (Basket / Umbrella / Platform) ](/terms/master-protocol) - [Real-World Data(RWD) ](/terms/rwd) - [Contract Research Organization(CRO) ](/terms/cro) - [Investigator-Initiated Trial(IIT) ](/terms/investigator-initiated-trial) [All Clinical & Trials terms](/terms?cat=Clinical%20%26%20Trials) From the Blue Goat network Related resources and services on this topic. - [ MedTech Launchpad MedTech funding rounds, accelerators, and launch resources. ](https://medtechlaunchguide.com) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)